Nalaganje...
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells
The combination of gemcitabine (Gem), busulfan (Bu) and melphalan (Mel) is a promising regimen for autologous stem-cell transplantation (SCT) for lymphomas. To further improve the efficacy of [Gem+Bu+Mel], we added PARP inhibitor olaparib (Ola). We hypothesized that Ola would inhibit the repair of d...
Shranjeno v:
| izdano v: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5526721/ https://ncbi.nlm.nih.gov/pubmed/28394191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1306647 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|